$0.27
2.86% yesterday
Nasdaq, Jul 05, 10:03 pm CET
ISIN
US55234L1052
Symbol
LYRA
Sector
Industry

Lyra Therapeutics Inc Target price 2024 - Analyst rating & recommendation

Lyra Therapeutics Inc Classifications & Recommendation:

Buy
20%
Hold
80%

Lyra Therapeutics Inc Price Target

Target Price $1.25
Price $0.27
Potential
Number of Estimates 2
2 Analysts have issued a price target Lyra Therapeutics Inc 2025 . The average Lyra Therapeutics Inc target price is $1.25. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 5 analysts: 1 Analysts recommend Lyra Therapeutics Inc to buy, 4 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Lyra Therapeutics Inc stock has an average upside potential 2025 of . Most analysts recommend the Lyra Therapeutics Inc stock at Hold.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 1.56 1.59
14.71% 1.64%
Net Margin -4,923.69% -4,459.74%
39.97% 9.42%

5 Analysts have issued a sales forecast Lyra Therapeutics Inc 2024 . The average Lyra Therapeutics Inc sales estimate is

$1.6m
Unlock
. This is
5.62% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$2.1m 26.67%
Unlock
, the lowest is
$500k 70.24%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $1.6m 14.71%
2024
$1.6m 1.64%
Unlock
2025
$809k 48.99%
Unlock
2026
$8.1m 899.80%
Unlock
2027
$34.3m 323.78%
Unlock
2028
$124m 263.22%
Unlock

1 Analyst has issued a net profit forecast Lyra Therapeutics Inc 2024 . The average Lyra Therapeutics Inc net profit estimate is

$-70.7m
Unlock
. This is
7.20% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-70.7m 7.20%
Unlock
, the lowest is
$-70.7m 7.20%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-76.8m 31.15%
2024
$-70.7m 7.94%
Unlock
2025
$-62.8m 11.20%
Unlock
2026
$-44.5m 29.13%
Unlock

Net Margin

2023 -4,923.69% 39.97%
2024
-4,459.74% 9.42%
Unlock
2025
-7,763.20% 74.07%
Unlock
2026
-550.32% 92.91%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -1.26 -1.16
31.15% 7.94%
P/E negative
EV/Sales negative

1 Analysts have issued a Lyra Therapeutics Inc forecast for earnings per share. The average Lyra Therapeutics Inc <a href=/blog/eps>EPS is

$-1.16
Unlock
. This is
7.20% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=/blog/eps>EPS forecast is
$-1.16 7.20%
Unlock
, the lowest is
$-1.16 7.20%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-1.26 31.15%
2024
$-1.16 7.94%
Unlock
2025
$-1.03 11.21%
Unlock
2026
$-0.73 29.13%
Unlock

P/E ratio

Current -0.22 88.17%
2024
-0.23 4.55%
Unlock
2025
-0.26 13.04%
Unlock
2026
-0.37 42.31%
Unlock

Based on analysts' sales estimates for 2024, the Lyra Therapeutics Inc stock is valued at an <a href=/blog/ev-sales-einfach-erklaert>EV/Sales of

-20.61
Unlock
and an <a href=/blog/kurs-umsatz-verhaeltnis-kuv-einfach-erklaert>P/S ratio of
10.46
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current -19.45 150.73%
2024
-20.61 5.97%
Unlock
2025
-40.41 96.04%
Unlock
2026
-4.04 90.00%
Unlock
2027
-0.95 76.40%
Unlock
2028
-0.26 72.46%
Unlock

P/S ratio

Current 9.87 90.12%
2024
10.46 5.95%
Unlock
2025
20.50 96.04%
Unlock
2026
2.05 90.00%
Unlock
2027
0.48 76.40%
Unlock
2028
0.13 72.47%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today